Rivaroxaban reduces major bleeding in patients with venous thromboembolism

10/15/2013 | Healio (free registration)

Rivaroxaban worked as well as standard treatment for patients with symptomatic venous thromboembolism with a significantly lower rate of major bleeding events. About 4,100 patients each received rivaroxaban or standard therapy, and researchers reported 40 major bleeding incidents with rivaroxaban and 72 with standard treatment.

View Full Article in:

Healio (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC